MANUSCRIPTS

Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.

Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW

J Am Coll Cardiol - 2006.

Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist:
a randomized double-blind multicenter trial.

Gerbes AL, Gülberg V, Ginès P, Decaux G, Gross P, Gandjini H, Djian J;
VPA Study Group.

Gastroenterology - 2003.

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.

Wong F, Blei AT, Blendis LM, Thuluvath PJ

Hepatology - 2003.

Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.

Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP.

Hepatology - 2002.

Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.

Decaux G

J Lab Clin Med - 2001.

Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients w ith chronic heart failure.

Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, Schrier RW

J Am Soc Nephrol - 1999.

MEETING PRESENTATIONS/POSTERS

114 Study Abstract

WT Abraham, Goldsmith S, Gottlieb S

- 2008.

ARCHIVES

The effects of VPA-985, a vasopressin receptor antagonist on water metabolism in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial

Wong F.

AGA - 2000.

Pharmacodynamic (PD) effects of a novel, non-peptide, V2 receptor antagonist, VPA-385 (VPA), given with hydrochlorothiazide (H)

Patat A, et al.

ASCPT - 2000.

Treatment of hyponatremia (HYPO) with VPA-985

Gross P, et al.

ASN - 1999.

VPA-985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double-blind placebo controlled multicenter trial.

Gerbes AL, et al.

AASLD - 1999.

Difference in solute excretion during correction of hyponatremic patients related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, VPA-985

Decaux G, et al.

ASN - 1999.

Pharmacodynamic effects of VPA-985, an ADH (V2) antagonist, in normal volunteers

Swan SK, et al.

ASN - 1999.

Interaction between VPA-985, an ADH (V2) antagonist, and furosemide

Swan SK, et al.

ASN - 1999.

VPA-985: A novel non-peptide competitive vasopressin receptor antagonist for the treatment of dilutional hyponatremia

Epstein M, et al.

ASN - 1999.

Pharmacokinetics and pharmacodynamics of a novel vasopressin receptor antagonist, VPA-985, in healthy subjects

Muralidharan G, et al.

ASCPT - 1999.

In vitro pharmacology of VPA-985, a non-peptide V2 selective vasopressin antagonist

Park CH, et al.

ASN - 1998.

Pharmacological characterization of VPA-985, a potent nonpeptidic orally-active and selective vasopressin (AVP) V2 receptor antagonist.

Chan PS, et al.

ASN - 1998.

Beneficial effects of V2-vasopressin antagonist (ANTAG) in the hyponatremia of clinical cardiac failure (CHF), SIADH and liver cirrhosis (CI) [Abstract 183].

Kuhn K, Reimann D, Gross

Kidney Blood Pressure Res - 1998.

Effects of an oral, nonpeptide, selective V-2 receptor vasopressin antagonist in patients with chronic heart failure.

Abraham WT, et al.

ACC - 1997.

Effects of an oral nonpeptide, selective V2 receptor vasopressin antagonist in human heart failure [Abstract 183]

Abraham WT, Oren RM, Schrier RW

World Congress of Neurohypo-physeal Hormones - 1997.

Characterization of VPA-985 as a specific, nonpeptide vasopressin V2 antagonist. [Abstract 181]

Coupet J, Mazandarini H, Albright JD, Dusza JP.

World Congress of Neurohypo-physeal Hormones - 1997.

OTHER

Managing Hyponatremia in Heart Failure

Abraham WT

Touch Briefing’s US Cardiovascular Disease - 2008.

Back To Top